This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jeffrey Wasserstein Joins Greenhill As Managing Director Focused On The Pharmaceutical Sector

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Greenhill & Co., Inc. (NYSE: GHL), a leading independent investment bank, announced today that Jeffrey Wasserstein has joined the Firm in New York to enhance its focus on the pharmaceutical sector.

Mr. Wasserstein has a 20 year history in the pharmaceutical industry in corporate development and commercial operating roles for a series of pharmaceutical companies.  Most recently he served as Senior Vice President of Business Development & Strategy at Fougera Pharmaceuticals, which was recently sold to the Sandoz division of Novartis AG.  Prior to his time at Fougera he spent five years at Dr. Reddy's Laboratories, a leading global generic pharmaceutical company, as founder and President of a branded specialty pharmaceutical subsidiary focused on dermatology as well as the Executive Vice President of North America and a member of Dr. Reddy's Global Management Council.  He began his career in the sector at Schering-Plough Corporation, where he started in a legal role and rose to first head of Corporate Business Development, then President of Schering Canada and later Senior Vice President of the parent company.  Prior to his time at Schering-Plough, he was an attorney at Wachtell, Lipton, Rosen & Katz for six years, focused on mergers and acquisitions advice.

Scott L. Bok, Chief Executive Officer of Greenhill, said, "The health care sector has become a very important part of our business, as an increasing number of companies in health care services, health care devices and pharmaceuticals have opted for our unconflicted, client-focused approach to advising clients on important transactions.  With the addition of Jeff we are significantly increasing our knowledge of the trends and opportunities in the pharmaceutical sector, as well as our access to a much larger range of companies in that sector."

Jeffrey Wasserstein said, "I am very pleased to be joining Greenhill, where I have known some of its partners for many years.  In my new role I can build upon my many relationships in the industry as well as my significant experience as a corporate development and operating executive and as an external advisor.  I look forward to utilizing my deep industry knowledge, an insider's appreciation for the many challenges facing the senior management and boards of companies in the pharmaceutical sector and my significant transaction experience to advise pharmaceutical companies on important transactions and other matters."

Greenhill & Co., Inc. is a leading independent investment bank focused on providing financial advice on significant mergers, acquisitions, restructurings, financings and capital raising to corporations, partnerships, institutions and governments.  It acts for clients located throughout the world from its offices in New York, London, Frankfurt, Stockholm, Sydney, Tokyo, Toronto, Chicago, Dallas, Houston, Los Angeles, Melbourne and San Francisco.

Contact: Christopher T. GrubbChief Financial Officer Greenhill & Co., Inc. (212) 389-1800

SOURCE Greenhill & Co., Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs